[go: up one dir, main page]

GB202403746D0 - Formulations demonstrating an oral depot effect - Google Patents

Formulations demonstrating an oral depot effect

Info

Publication number
GB202403746D0
GB202403746D0 GBGB2403746.7A GB202403746A GB202403746D0 GB 202403746 D0 GB202403746 D0 GB 202403746D0 GB 202403746 A GB202403746 A GB 202403746A GB 202403746 D0 GB202403746 D0 GB 202403746D0
Authority
GB
United Kingdom
Prior art keywords
depot effect
formulations demonstrating
oral depot
oral
demonstrating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB2403746.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Travers Glen Nicholas
Original Assignee
Travers Glen Nicholas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Travers Glen Nicholas filed Critical Travers Glen Nicholas
Priority to GBGB2403746.7A priority Critical patent/GB202403746D0/en
Publication of GB202403746D0 publication Critical patent/GB202403746D0/en
Priority to PCT/IB2025/052703 priority patent/WO2025191523A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB2403746.7A 2024-03-15 2024-03-15 Formulations demonstrating an oral depot effect Pending GB202403746D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2403746.7A GB202403746D0 (en) 2024-03-15 2024-03-15 Formulations demonstrating an oral depot effect
PCT/IB2025/052703 WO2025191523A1 (en) 2024-03-15 2025-03-14 Formulations demonstrating an oral depot effect

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2403746.7A GB202403746D0 (en) 2024-03-15 2024-03-15 Formulations demonstrating an oral depot effect

Publications (1)

Publication Number Publication Date
GB202403746D0 true GB202403746D0 (en) 2024-05-01

Family

ID=90826163

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2403746.7A Pending GB202403746D0 (en) 2024-03-15 2024-03-15 Formulations demonstrating an oral depot effect

Country Status (2)

Country Link
GB (1) GB202403746D0 (en)
WO (1) WO2025191523A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP4400094A4 (en) * 2021-09-07 2025-08-27 D&D Pharmatech Inc Pharmaceutical composition containing major physiologically active substance and excipient

Also Published As

Publication number Publication date
WO2025191523A1 (en) 2025-09-18

Similar Documents

Publication Publication Date Title
IL318706A (en) Compositions and methods for inducing ferroptosis
GB202403746D0 (en) Formulations demonstrating an oral depot effect
GB202210794D0 (en) Lipid formulations
ZA202408364B (en) Liquid-dispersible halopyruvate formulations and associated methods
GB202417829D0 (en) Formulations
GB202306966D0 (en) Oral thin film formulations
IL321617A (en) Bezuclastinib formulations
GB202315863D0 (en) Formulations
GB202307059D0 (en) Formulations
GB202216961D0 (en) 5-meo-mt formulations
GB202406554D0 (en) Stable latex formulations
GB202306393D0 (en) Trna-based methods and related compositions
CA3272381A1 (en) Oral compositions and related methods
GB202417250D0 (en) Pharmaceutical formulations
GB202511336D0 (en) Compositions and methods
GB202511056D0 (en) Compositions and methods
GB202508914D0 (en) Compositions and methods
GB202508655D0 (en) Compositions and methods
GB202508119D0 (en) Compositions and methods
GB202507586D0 (en) Compositions and methods
GB202507139D0 (en) Methods and compositions
GB202504125D0 (en) Methods and compositions
GB202501142D0 (en) Methods and compositions
GB202500680D0 (en) Methods and compositions
GB202418179D0 (en) Compositions and methods